|
106 |
The changing patterns of cardiovascular diseases and their risk factors in the states of India: the Global Burden of Disease Study 1990-2016 |
Prabhakaran D, Jeemon P, Sharma M, Roth GA, Johnson C, Harikrishnan S, Gupta R, Pandian JD, Naik N, Roy A, Dhaliwal RS, Xavier D, et al; India State-Level Disease Burden Initiative CVD Collaborators |
Lancet Glob Health |
2018 |
|
107 |
Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017 |
Roth GA, Abate D, Abate KH, Abay SM, Xavier D, et.al; GBD 2017 Causes of Death Collaborators |
Lancet |
2018 |
|
108 |
Community Health Worker Interventions in Type 2 Diabetes Mellitus Patients: Assessing the Feasibility and Effectiveness in Rural Central India |
Jain V, Joshi R, Idiculla J, Xavier D |
Journal of Cardiovascular Disease Research |
2018 |
|
109 |
Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 |
Stanaway JD, Afshin A, Gakidou E, Lim SS, Xavier D, et.al; GBD 2017 Risk Factor Collaborators |
Lancet |
2018 |
|
110 |
The increasing burden of diabetes and variations among the states of India: the Global Burden of Disease Study 1990–2016
|
Nikhil Tandon, Ranjit M Anjana, Viswanathan Mohan, Tanvir Kaur, Ashkan Afshin, Kanyin Ong, Satinath Mukhopadhyay, Nihal Thomas, Eesh Bhatia, Anand Krishnan, Prashant Mathur, R S Dhaliwal, D K Shukla, Anil Bhansali, Dorairaj Prabhakaran, Paturi V Rao, Chittaranjan S Yajnik, *Denis Xavier*, et al..
|
The Lancet Global Health |
2018 |
|
111 |
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 |
Spencer L James, Degu Abate, Kalkidan Hassen Abate, *Denis Xavier*, et al .. |
The Lancet |
2018 |
|
112 |
Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 STUDY |
*Pais P*, Jung H, Dans A, Zhu J, Liu L, *Kamath D*, Bosch J, Lonn E & Yusuf S, *Denis Xavier*, et al.. |
Eur J Prev Cardiol |
2018 |
|
113 |
Impact of a multifaceted educational intervention on oral anticoagulation (OAC) use in atrial fibrillation (AF) patients according to aspirin use at baseline: insights from impact-AF trial. |
Jie Jiang, Ying Xian, Hussein Al-Khalidi, Maria Bahit, Renato Lopes, Dragos Vinereanu, *Denis Xavier*, He Pengkang, He Wensheng, Andrea Ciobanu, *Deepak Kamanth*, et al.. |
Journal of the American College of Cardiology |
2018 |
|
114 |
Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health- related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. |
Rafael Lozano, Nancy Fullman, Degu Abate, Solomon M Abay, Cristiana Abbafati, *Denis Xavier*, et al.. |
The Lancet |
2018 |
|
115 |
Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study |
Langhorne P, O'Donnell MJ, Chin SL, Zhang H, Xavier D, Avezum A, Mathur N, Turner M, MacLeod MJ, Yusuf S, et al; NTERSTROKE collaborators |
Lancet |
2018 |
|
116 |
Aspirin in Patients With Previous Percutaneous Coronary Intervention Undergoing Noncardiac Surgery |
Graham MM, Sessler DI, Parlow JL, Biccard BM, Guyatt G, Leslie K, Chan MTV, Meyhoff CS, Xavier D, Sigamani A, Kumar PA, Mrkobrada M, Cook DJ, Tandon V, Alvarez-Garcia J, Villar JC, Painter TW, Landoni G, Fleischmann E, Lamy A, Whitlock R, Le Manach Y, Aphang-Lam M, Cata JP, Gao P, Terblanche NCS, Ramana PV, Jamieson KA, Bessissow A, Mendoza GR, Ramirez S, Diemunsch PA, Yusuf S, Devereaux PJ |
Ann Intern Med |
2018 |
|
117 |
Improving Evidence for Implementation of Guideline-Based Care in Low- and Middle-Income Countries |
Granger CB, Xavier D |
JAMA |
2018 |
|
118 |
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide |
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riddle MC, Rydén L, Xavier D, Atisso CM, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona-Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw J, Sheu WH, Temelkova-Kurktschiev T; REWIND Trial Investigators. |
Diabetes Obes Metab |
2018 |
|
119 |
Design of a Randomized Placebo-Controlled Trial to Assess Dabigatran and Omeprazole in Patients with Myocardial Injury after Noncardiac Surgery (MANAGE) |
Duceppe E, Yusuf S, Tandon V, Rodseth R, Biccard BM, Xavier D, Szczeklik W, Meyhoff CS, Franzosi MG, Vincent J, Srinathan SK, Parlow J, Magloire P, Neary J, Rao M, Chaudhry NK, Mayosi B, de Nadal M, Popova E, Villar JC, Botto F, Berwanger O, Guyatt G, Eikelboom JW, Sessler DI, Kearon C, Pettit S, Connolly SJ, Sharma M, Bangdiwala SI, Devereaux PJ |
Can J Cardiol |
2018 |
|
120 |
Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes |
Everett BM, Donath MY, Pradhan AD, Thuren T, Pais P, Nicolau JC, Glynn RJ, Libby P, Ridker PM |
J Am Coll Cardiol |
2018 |